Keyword Analysis & Research: checkmate 577
Keyword Research: People who searched checkmate 577 also searched
Search Results related to checkmate 577 on Search Engine
-
Adjuvant Nivolumab in Resected Esophageal or …
https://www.nejm.org/doi/full/10.1056/NEJMoa2032125
WEBMar 31, 2021 · We conducted CheckMate 577, a global, randomized, double-blind, placebo-controlled phase 3 trial to evaluate a checkpoint inhibitor as adjuvant therapy in patients … Author: Ronan J. Kelly, Jaffer A. Ajani, Jaroslaw Kuzdzal, Thomas Zander, Eric van Cutsem, Guillaume Piessen... Publish Year: 2021
Author: Ronan J. Kelly, Jaffer A. Ajani, Jaroslaw Kuzdzal, Thomas Zander, Eric van Cutsem, Guillaume Piessen...
Publish Year: 2021
DA: 80 PA: 69 MOZ Rank: 41
-
Adjuvant Nivolumab in Resected Esophageal or …
https://pubmed.ncbi.nlm.nih.gov/33789008/
WEBApr 1, 2021 · Methods: We conducted CheckMate 577, a global, randomized, double-blind, placebo-controlled phase 3 trial to evaluate a checkpoint inhibitor as adjuvant therapy … Author: Ronan J. Kelly, Jaffer A. Ajani, Jaroslaw Kuzdzal, Thomas Zander, Eric van Cutsem, Guillaume Piessen... Publish Year: 2021
Author: Ronan J. Kelly, Jaffer A. Ajani, Jaroslaw Kuzdzal, Thomas Zander, Eric van Cutsem, Guillaume Piessen...
Publish Year: 2021
DA: 81 PA: 1 MOZ Rank: 25
-
FDA approves nivolumab for resected esophageal or …
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-resected-esophageal-or-gej-cancer
WEBThe FDA approved nivolumab (Opdivo) for patients with resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease who have …
DA: 5 PA: 18 MOZ Rank: 92
-
Adjuvant nivolumab (NIVO) in resected esophageal or …
https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.4003
WEBAdjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and … Author: Ronan Joseph Kelly, Jaffer A. Ajani, Jaroslaw Kuzdzal, Thomas Zander, Eric Van Cutsem, Guillaume Pie... Publish Year: 2021
Author: Ronan Joseph Kelly, Jaffer A. Ajani, Jaroslaw Kuzdzal, Thomas Zander, Eric Van Cutsem, Guillaume Pie...
Publish Year: 2021
DA: 16 PA: 41 MOZ Rank: 76
-
CheckMate -577, a Phase 3 Trial Evaluating Opdivo …
https://news.bms.com/news/details/2020/CheckMate--577-a-Phase-3-Trial-Evaluating-Opdivo-nivolumab-as-Adjuvant-Therapy-for-Patients-with-Resected-Esophageal-or-Gastroesophageal-Junction-Cancer-Meets-Primary-Endpoint-of-Disease-Free-Survival/default.aspx
WEBAug 11, 2020 · CheckMate -577 is a Phase 3 randomized, multi-center, double-blind study evaluating Opdivo as an adjuvant therapy in patients with resected esophageal or GEJ …
DA: 79 PA: 28 MOZ Rank: 46
-
CheckMate 577: A randomized, double-blind, phase 3 study of …
https://ascopubs.org/doi/10.1200/JCO.2017.35.4_suppl.TPS212
WEBMar 21, 2017 · This multinational, double-blind, phase 3 trial will evaluate nivo as an adjuvant therapy for pts with resected E/GEJ cancer (CheckMate 577; NCT02743494). …
DA: 24 PA: 50 MOZ Rank: 57
-
CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as
https://news.bms.com/news/details/2020/CheckMate--577-a-Phase-3-Trial-Evaluating-Opdivo-nivolumab-as-Adjuvant-Therapy-for-Patients-with-Resected-Esophageal-or-Gastroesophageal-Junction-Cancer-Meets-Primary-Endpoint-of-Disease-Free-Survival/default.aspx
DA: 73 PA: 12 MOZ Rank: 3
-
Nivolumab adjuvant therapy for esophageal cancer: a …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582756/
WEBOct 4, 2023 · The CheckMate 577 trial demonstrates that nivolumab adjuvant therapy improves disease-free survival in patents without a pathological complete response. …
DA: 98 PA: 44 MOZ Rank: 83
-
CheckMate 577: A randomized, double-blind, phase 3 study of …
https://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.TPS4131
WEBMay 30, 2017 · CheckMate 577: A randomized, double-blind, phase 3 study of adjuvant nivolumab (nivo) or placebo in pts with resected esophageal (E) or gastroesophageal …
DA: 20 PA: 29 MOZ Rank: 89
-
e new england journal o medicine
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2032125
WEBWe conducted CheckMate 577, a global, randomized, double-blind, placebo-con-trolled phase 3 trial to evaluate a checkpoint inhibitor as adjuvant therapy in patients with …
DA: 72 PA: 81 MOZ Rank: 93
-
LBA9_PR Adjuvant nivolumab in resected esophageal or …
https://www.annalsofoncology.org/article/S0923-7534(20)42381-6/fulltext
WEBCheckMate 577 is the first global, randomized, double-blind, phase 3 study to report the efficacy and safety of a checkpoint inhibitor in the adjuvant setting after trimodality …
DA: 17 PA: 61 MOZ Rank: 68
